Latest information on COVID-19
Support teaching, research, and patient care.
Currently performing an analysis of actual versus predicted HLA antigen frequency in pediatric versus adult and various regions in the United States.This research represents an effort to better predict wait time for children listed for heart transplantation at Lucile Packard Children's Hospital, Stanford.
Palo Alto, CA
Study funde by the Lucile Packard Foundation Children With Special Health Care Needs Grant.
Currently investigating the incidence and risk factors for kidney injury in the pediatric heart transplant population.
Stanford, CA
Outcomes, Quality of Life, Kidney Injury
Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score Not Recruiting
The TEAMMATE Trial will enroll 210 pediatric heart transplant patients from 25 centers at 6 months post-transplant and follow each patient for 2.5 years. Half of the participants will receive everolimus and low-dose tacrolimus and the other half will receive tacrolimus and mycophenolate mofetil. The trial will determine which treatment is better at reducing the cumulative risk of coronary artery vasculopathy, chronic kidney disease and biopsy proven-acute cellular rejection without an increase in graft loss due to all causes (e.g. infection, PTLD, antibody mediated rejection).
Stanford is currently not accepting patients for this trial. For more information, please contact Seth Hollander, MD, 650-736-8600.
View full details
Pediatric Heart Transplantation: Transitioning to Adult Care Not Recruiting
The purpose of this pilot trial, Transitioning to Adult Care (TRANSIT), is to develop and test an intervention (i.e., a standardized, tailored transition program focused on enhancing adherence) to improve outcomes for emerging adults who underwent heart transplantation as children and transfer to adult care.
Stanford is currently not accepting patients for this trial. For more information, please contact SPECTRUM, 650-736-8600.
